scholarly journals Finding treatment-resistant depression in real-world data: How a data-driven approach compares with expert-based heuristics

2017 ◽  
Vol 35 (3) ◽  
pp. 220-228 ◽  
Author(s):  
M. Soledad Cepeda ◽  
Jenna Reps ◽  
Daniel Fife ◽  
Clair Blacketer ◽  
Paul Stang ◽  
...  
2017 ◽  
Vol 19 (1) ◽  
pp. 127-139 ◽  
Author(s):  
Jun Li ◽  
Eric M. Simmons ◽  
Martin D. Eastgate

A predictive analytics approach to understanding process mass intensity (PMI) is described. This method leverages real-world data to predict probable PMI outcomes for a potential synthetic route and to compare PMI outcomes to the summation of prior experience.


2017 ◽  
Vol 44 ◽  
pp. 61-67 ◽  
Author(s):  
K. Feffer ◽  
K.A.B. Lapidus ◽  
Y. Braw ◽  
Y. Bloch ◽  
S. Kron ◽  
...  

AbstractBackground:Deep transcranial magnetic stimulation (dTMS) has been sanctioned by the United States Food and Drug Administration for treatment-resistant depression. In a retrospective cohort study, we evaluated response and effectiveness of dTMS in real-world practice, as an add-on treatment for resistant depression.Methods:Forty adult outpatients suffering from depression, all taking psychiatric medications, underwent 20 dTMS treatments over a 4–6 week period. At baseline (T0), visit 10 (T1), and visit 20 (T2), the Clinical Global Impression-Severity (CGI-S) scale was administered, and the Clinical Global Impression Improvement (CGI-I) scale was completed at T1 and T2; the Hamilton Depression Rating Scale (HDRS-21) was administrated at T0 and T2 only. The patients also completed the Quick Inventory of Depressive Symptoms–Self-Report (QIDS-SR) at T0, T1, and T2.Results:Depressive symptoms (HDRS-21 total score) decreased significantly following treatment. The HDRS total score decreased from an average of 21.22 (± 6.09) at T0, to 13.95 (± 7.24) at T2. Correspondingly, at T2, 32.5% were responders to the treatment and 20% were in remission, based on the HDRS-21. Treatment was well tolerated, with a discontinuation rate of 7.5%. While depressive symptoms at baseline did not predict remission/response at T2, higher HDRS scores at T0 were associated with a larger decrease in depressive symptoms during the study.Conclusions:Significant antidepressant effects were seen following 20 dTMS treatments, given as augmentation to ongoing medications in treatment-resistant depression. The findings suggest that among patients with TRD, the severity of the depressive episode (and not necessarily the number of failed antidepressant medication trials) is associated with a positive therapeutic effect of dTMS. Hence, the initial severity of the depressive episode may guide clinicians in referring patients for dTMS.


2021 ◽  
pp. 114086
Author(s):  
Joshua D. Rosenblat ◽  
Orly Lipsitz ◽  
Joshua D. Di Vincenzo ◽  
Nelson B. Rodrigues ◽  
Kevin Kratiuk ◽  
...  

2021 ◽  
Vol 53 ◽  
pp. S71-S72
Author(s):  
E. Baca-García ◽  
V. Pérez-Sola ◽  
P. Sierra San Miguel ◽  
J. Morrens ◽  
C. Pagés Rivero ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document